Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.30 (
PARP
)
13,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SLC39A7
(zip7) is a zinc transporter that plays a key role in intestinal epithelial self-renewal. However, little is known about
SLC39A7
in colorectal cancer. To assess the biological function of
SLC39A7
in colorectal cancer, the expression of
SLC39A7
in human colorectal tumors and five colorectal cancer cell lines were evaluated by Oncomine Cancer Microarray Database and western blot analysis. In addition, short hairpin RNAs specifically targeting
SLC39A7
were transfected into HCT116 and SW1116 cells to knockdown
SLC39A7
expression. Then, the effects of
SLC39A7
knockdown on colorectal cancer cells were detected by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide, colony-forming assay and flow cytometry. Our results showed that colorectal tumors have higher expression levels of
SLC39A7
than normal colon tissues. Knockdown of
SLC39A7
exhibited a significant decrease in cell viability and proliferation of colorectal cancer cells. It was also shown that knockdown of
SLC39A7
interfered with cell cycle progression and induced G2/M cell cycle arrest, as well as boosted early and late apoptosis in colorectal cancer cells. Furthermore, downregulation of
SLC39A7
promoted the cleavage of
PARP
and enhanced the expression of Bad, Caspase-9, and cleaved-Caspase-3, as well as suppressed Bcl-2 expression. In conclusion, our results suggest that
SLC39A7
plays a crucial role in the proliferation and survival of colorectal cancer cells, which associates with colorectal tumorigenesis.
...
PMID:Knockdown of SLC39A7 inhibits cell growth and induces apoptosis in human colorectal cancer cells. 2898 7
